Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the
Sequential Treatment of Advanced Urothelial Carcinoma: The
ARON-2 Retrospective Experience

J 2025

Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

RIZZO, Mimma; Franco MORELLI; Yueksel URUN; Sebastiano BUTI; Se Hoon PARK et al.

Základní údaje

Originální název

Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

Autoři

Vydání

Cancer Medicine, Hoboken, Wiley, 2025, 2045-7634

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.100 v roce 2024

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/25:00143832

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

ARON-2 study; chemotherapy; enfortumab vedotin; NCT05290038; pembrolizumab; real-world data; sequencing; urothelial carcinoma

Štítky

14110811, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 2. 3. 2026 13:47, Mgr. Tereza Miškechová

Anotace

V originále

Background Recently, a plethora of novel systemic agents have been incorporated into the therapeutic armamentarium of advanced urothelial carcinoma (aUC). The antibody-drug conjugate (ADC), enfortumab vedotin (EV), has demonstrated relevant clinical benefit in patients with aUC refractory to platinum and immune-checkpoint inhibitor (ICI) therapy. Our study provides a retrospective, international, real-world analysis comparing the effectiveness of EV to chemotherapy in this setting. Methods The data were extracted from the medical records of patients treated with EV or chemotherapy following pembrolizumab for recurrent or progressive aUC after platinum-based chemotherapy. Patients were assessed for overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and duration of response (DoR). Results Our analysis included 247 patients treated with EV (88, 36%) or chemotherapy (159, 64%). Median OS was 9.1 months (95%CI 7.2-10.7) in the overall study population, 13.6 months (95%CI 10.0-31.0) in patients receiving EV and 6.8 months (95%CI 6.0-8.9) in patients receiving chemotherapy (p < 0.001). The OS benefit of EV was not affected by primary tumour site and histology, metastatic sites, type of first platinum-based chemotherapy or response to pembrolizumab. In the EV cohort, the median PFS was significantly longer (8.8 months [95%CI 6.5-17.0] vs. 3.0 months [95%CI 2.6-3.7]) and the ORR was significantly higher (56% vs. 23%) than in the chemotherapy cohort. Conclusions The results of our international analysis of real-world data confirm the effectiveness of EV in the sequential strategy of aUC patients who have received prior platinum-based chemotherapy and anti-PD-1 pembrolizumab, regardless of commonly considered prognostic factors. Trial Registration: identifier: NCT05290038

Citovat

RIZZO, Mimma; Franco MORELLI; Yueksel URUN; Sebastiano BUTI; Se Hoon PARK; Maria T BOURLON; Enrique GRANDE; Francesco MASSARI; Johannes LANDMESSER; Alexandr POPRACH; Hideki TAKESHITA; Giandomenico ROVIELLO; Zin W MYINT; Lazar POPOVIC; Andrey SOARES; Halima ABAHSSAIN; Patrizia GIANNATEMPO; Javier MOLINA-CERRILLO; Lorena INCORVAIA; Samer SALAH; Annalisa ZEPPELLINI; Fernando Sabino Marques MONTEIRO; Camillo PORTA; Shilpa GUPTA a Matteo SANTONI. Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience. Cancer Medicine. Hoboken: Wiley, 2025, roč. 14, č. 4, s. 1-12. ISSN 2045-7634. Dostupné z: https://doi.org/10.1002/cam4.70479.

@article{2557840,
   author = {Rizzo, Mimma and Morelli, Franco and Urun, Yueksel and Buti, Sebastiano and Park, Se Hoon and Bourlon, Maria T and Grande, Enrique and Massari, Francesco and Landmesser, Johannes and Poprach, Alexandr and Takeshita, Hideki and Roviello, Giandomenico and Myint, Zin W and Popovic, Lazar and Soares, Andrey and Abahssain, Halima and Giannatempo, Patrizia and MolinaandCerrillo, Javier and Incorvaia, Lorena and Salah, Samer and Zeppellini, Annalisa and Monteiro, Fernando Sabino Marques and Porta, Camillo and Gupta, Shilpa and Santoni, Matteo},
   article_location = {Hoboken},
   article_number = {4},
   doi = {https://doi.org/10.1002/cam4.70479},
   keywords = {ARON-2 study; chemotherapy; enfortumab vedotin; NCT05290038; pembrolizumab; real-world data; sequencing; urothelial carcinoma},
   language = {eng},
   issn = {2045-7634},
   journal = {Cancer Medicine},
   title = {Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience},
   url = {https://onlinelibrary.wiley.com/doi/10.1002/cam4.70479},
   volume = {14},
   year = {2025}
}

TY  - JOUR
ID  - 2557840
AU  - Rizzo, Mimma - Morelli, Franco - Urun, Yueksel - Buti, Sebastiano - Park, Se Hoon - Bourlon, Maria T - Grande, Enrique - Massari, Francesco - Landmesser, Johannes - Poprach, Alexandr - Takeshita, Hideki - Roviello, Giandomenico - Myint, Zin W - Popovic, Lazar - Soares, Andrey - Abahssain, Halima - Giannatempo, Patrizia - Molina-Cerrillo, Javier - Incorvaia, Lorena - Salah, Samer - Zeppellini, Annalisa - Monteiro, Fernando Sabino Marques - Porta, Camillo - Gupta, Shilpa - Santoni, Matteo
PY  - 2025
TI  - Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience
JF  - Cancer Medicine
VL  - 14
IS  - 4
SP  - 1-12
EP  - 1-12
PB  - Wiley
SN  - 20457634
KW  - ARON-2 study
KW  - chemotherapy
KW  - enfortumab vedotin
KW  - NCT05290038
KW  - pembrolizumab
KW  - real-world data
KW  - sequencing
KW  - urothelial carcinoma
UR  - https://onlinelibrary.wiley.com/doi/10.1002/cam4.70479
N2  - Background Recently, a plethora of novel systemic agents have been incorporated into the therapeutic armamentarium of advanced urothelial carcinoma (aUC). The antibody-drug conjugate (ADC), enfortumab vedotin (EV), has demonstrated relevant clinical benefit in patients with aUC refractory to platinum and immune-checkpoint inhibitor (ICI) therapy. Our study provides a retrospective, international, real-world analysis comparing the effectiveness of EV to chemotherapy in this setting. Methods The data were extracted from the medical records of patients treated with EV or chemotherapy following pembrolizumab for recurrent or progressive aUC after platinum-based chemotherapy. Patients were assessed for overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and duration of response (DoR). Results Our analysis included 247 patients treated with EV (88, 36%) or chemotherapy (159, 64%). Median OS was 9.1 months (95%CI 7.2-10.7) in the overall study population, 13.6 months (95%CI 10.0-31.0) in patients receiving EV and 6.8 months (95%CI 6.0-8.9) in patients receiving chemotherapy (p < 0.001). The OS benefit of EV was not affected by primary tumour site and histology, metastatic sites, type of first platinum-based chemotherapy or response to pembrolizumab. In the EV cohort, the median PFS was significantly longer (8.8 months [95%CI 6.5-17.0] vs. 3.0 months [95%CI 2.6-3.7]) and the ORR was significantly higher (56% vs. 23%) than in the chemotherapy cohort. Conclusions The results of our international analysis of real-world data confirm the effectiveness of EV in the sequential strategy of aUC patients who have received prior platinum-based chemotherapy and anti-PD-1 pembrolizumab, regardless of commonly considered prognostic factors. Trial Registration: identifier: NCT05290038
ER  -

RIZZO, Mimma; Franco MORELLI; Yueksel URUN; Sebastiano BUTI; Se Hoon PARK; Maria T BOURLON; Enrique GRANDE; Francesco MASSARI; Johannes LANDMESSER; Alexandr POPRACH; Hideki TAKESHITA; Giandomenico ROVIELLO; Zin W MYINT; Lazar POPOVIC; Andrey SOARES; Halima ABAHSSAIN; Patrizia GIANNATEMPO; Javier MOLINA-CERRILLO; Lorena INCORVAIA; Samer SALAH; Annalisa ZEPPELLINI; Fernando Sabino Marques MONTEIRO; Camillo PORTA; Shilpa GUPTA a Matteo SANTONI. Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience. \textit{Cancer Medicine}. Hoboken: Wiley, 2025, roč.~14, č.~4, s.~1-12. ISSN~2045-7634. Dostupné z: https://doi.org/10.1002/cam4.70479.

Přehled o publikaci